Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The Japanese drugmaker Kyowa Kirin will pay San Diego–based MEI Pharma $100 million up front and up to $583 million in milestone payments to develop and commercialize its experimental blood-cancer drug, MEI-401. The compound, a small-molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, is being tested in a Phase II study of follicular lymphoma and a Phase I study of B-cell malignancies. The firms will split costs and profits in the US, while Kyowa Kirin has exclusive rights to the drug everywhere else.
This article has been sent to the following recipient: